Scientific publications on MPNs

Below is a chronological list of scientific articles related to polycythemia vera, essential thrombocythemia and myelofibrosis. Where possible we have linked to abstracts and complete articles. If you are unable to download an article you are interested in please contact the publisher directly.


  • The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis. Rafael Kramann and Rebekka K. Schneider Blood 2018 (Current MPNRF grantee)
  • Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN Mullally et al. Blood 2018 
  • The role of JAK2 inhibitors in MPN seven years after approval. Francesco Passamonti  and  Margherita  Maffioli Blood 2018 Click here to read more.
  • Views on Bone Marrow Transplant: A Survey of Patients with Myelofibrosis. Mesa, et al. Biology of Blood and Marrow Transplantation 2018. 
  • Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. Green, et al. Blood 2018. Click here to read more.


  • Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Verstovsek, et al. Blood 2017 Click here to read more.
  • Open Label Phase I Study of Single Agent Oral RG7388 (idasanutlin) in Patients with Polycythemia Vera and Essential Thrombocythemia Blood 2017 Click here to read more.
  • Efficacy of ALK5 inhibition in myelofibrosis. Pearlie Epling-Burnette, Amit Verma, et al. JCI Insight. 2017 Apr 6; 2(7)
  • Which Patients with Myelofibrosis Should Receive Allogeneic Stem Cell Transplantation? A Decision Analysis Based on the Systematic Review of 4,341 Patients. Monia Marchetti and Nicolaus Kroeger Blood 2017 Click here to read more
  • Myeloproliferative Neoplasm Stem Cells. Adam J. Mead and Ann Mullally.  Blood 2017 Click here to read more
  • Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge? Salit RB1, Deeg HJ2. Biol Blood Marrow Transplant. 2018 Click here to read more.


  • Generation, Characterization and Genetic Modification of human iPSCs Containing Calr, MPL and JAK2 Mutations Found in MPN Patients Click here to read more.
  • Promedior Announces Completion of Patient Enrollment Milestones in Phase 2 Clinical Studies of PRM-151 in Both Idiopathic Pulmonary Fibrosis and Myelofibrosis
  • Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients Click here to read more
  • Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status Click here to read more
  • Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl Click here to read more
  • Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial Click here to read more
  • Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia The following chart was presented on interim data Click here to read more
  • New MRI-focused approach to detecting myelofibrosis. Health Imaging. Nov 14, 2016 Click here to read more








  • Epidemiology of Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders in the United States, 2011-2004, Using Data from the NAACCR and SEER Programs. Rollison, Dana E., et al. Blood 2008 112: 45-52
  • Population-Based Incidence and Survival Figures in Essential Thrombocythemia and Agnogenic  Myeloid Metaplasia: An Olmsted Country Study, 1976-1995. Mesa, Ruben A., et al. American Journal of Hematology 61:10-15 (1999)
  • Prevalence of polycythemia vera and essential thrombocythemia. Xiaomei Ma, et al. American Journal of Hematology. 2008 May;83(5):359-62.
  • Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors. Ifat Geron, et al. Cancer Cell 13, 321–330, April 2008
  • Effïcacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera. Gerlinde Wernig, et al. Cancer Cell 13, 311–320, April 2008
  • Chronic myeloproliferative disorders in childhood. Georgina W. Hall. Myeloproliferative Disorders in Practice 2008. Vol 2., No. 2





  • Agent orange and cancer: an overview for clinicians. Howard Frumkin. Volume 53 Y Number 4 Y July/August 2003 2


2000 & Earlier

Take the steps you need to help change your prognosis.